Bristol-Myers Squibb’s patent infringement suit against Merck over a new cancer treatment can move forward, a Delaware federal judge has ruled.
In Bristol-Myers Squibb v. Merck & Co., U.S. District Judge Gregory M. Sleet of the District of Delaware denied Merck’s motion to dismiss Bristol-Myers’ complaint. Merck argued that Bristol-Myers’ patent for the cancer treatment was not valid.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]